Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00087490 · ClinicalTrials.gov registry record · Phase 4

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

A Phase 4 study of Skin/Soft Tissue Infections and Methicillin Resistant Staphylococcus Aureus (MRSA), sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
1,077
Enrollment target
20
Study locations

NCT00087490 is a Phase 4 study of Skin/Soft Tissue Infections and Methicillin Resistant Staphylococcus Aureus (MRSA) that has completed, run by Pfizer. The registered enrollment target is 1,077 participants. The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00087490, a Phase 4 study of Skin/Soft Tissue Infections and Methicillin Resistant Staphylococcus Aureus (MRSA), has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
1,077 participants
Enrollment target
20
Study locations

Study Summary

To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects

Conditions Studied

Skin/Soft Tissue Infections Methicillin Resistant Staphylococcus Aureus (MRSA)

Interventions

  • DRUG linezolid
  • DRUG vancomycin

Study Locations (20)

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Palm Springs
  • Pfizer Investigational Site - Rancho Mirage
  • Pfizer Investigational Site - San Pedro
  • Pfizer Investigational Site - Santa Fe Springs
  • Pfizer Investigational Site - Sylmar
  • Pfizer Investigational Site - Torrance
  • Pfizer Investigational Site - Torrance
  • Pfizer Investigational Site - Torrance

Connecticut

  • Pfizer Investigational Site - Hartford
  • Pfizer Investigational Site - Hartford
  • Pfizer Investigational Site - New Haven
  • Pfizer Investigational Site - New Haven

Florida

  • Pfizer Investigational Site - Atlantis
  • Pfizer Investigational Site - Melbourne
  • Pfizer Investigational Site - Miami

Colorado

  • Pfizer Investigational Site - Denver
  • Pfizer Investigational Site - Denver

Alabama

  • Pfizer Investigational Site - Montgomery

Arizona

  • Pfizer Investigational Site - Tucson

Trial Details

FieldValue
Enrollment Target 1,077 participants
Start Date 2004-10
Est. Completion 2007-07
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00087490

The ClinicalTrials.gov registry entry for NCT00087490 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,077 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Skin/Soft Tissue Infections appearing as the primary indexed condition, and to 2 interventions - of which linezolid is the first listed.

NCT00087490 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Connecticut, Florida.

Frequently Asked Questions

What is clinical trial NCT00087490 about?

NCT00087490 is a clinical study titled "Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)". To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects

What is the current status of trial NCT00087490?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,077 participants. The study started on 2004-10. Estimated completion is 2007-07.

What conditions does trial NCT00087490 study?

This clinical trial studies the following conditions: Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA).

What interventions are being tested in trial NCT00087490?

The interventions under investigation include: linezolid (DRUG), vancomycin (DRUG).

Who is sponsoring clinical trial NCT00087490?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00087490 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Explore more on PlainTrial

Skin/Soft Tissue Infections

All registered trials for this condition

Methicillin Resistant Staphylococcus Aureus (MRSA)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.